Literature DB >> 27021586

Anti-programmed Death Receptor 1 Blockade Induces Clinical Response in a Patient With Metastatic Collecting Duct Carcinoma.

Kalen J Rimar1, Joshua J Meeks2, Timothy M Kuzel3.   

Abstract

Entities:  

Keywords:  Collecting duct carcinoma; Metastatic renal cell carcinoma; Nivolumab; Non–clear cell renal cell carcinoma; PD1 inhibitor

Mesh：

Substances：

Year:  2016        PMID： 27021586     DOI： 10.1016/j.clgc.2016.02.013

Source DB:  PubMed          Journal:  Clin Genitourin Cancer        ISSN： 1558-7673            Impact factor:   2.872


× No keyword cloud information.
  8 in total

Review 1.  Nivolumab in renal cell carcinoma: latest evidence and clinical potential.

Authors:  Camille Mazza; Bernard Escudier; Laurence Albiges
Journal:  Ther Adv Med Oncol       Date:  2016-12-11       Impact factor: 8.168

2.  Complete response to combination therapy using nivolumab and ipilimumab for metastatic, sarcomatoid collecting duct carcinoma presenting with high expression of programmed death-ligand 1: a case report.

Authors:  Takayoshi Fuu; Kazuyoshi Iijima; Yukiko Kusama; Toshiaki Otsuki; Haruaki Kato
Journal:  J Med Case Rep       Date:  2022-05-18

3.  Complete response to combination therapy with nivolumab and ipilimumab for metastatic collecting duct carcinoma of the kidney.

Authors:  Kyohei Watanabe; Takayuki Sugiyama; Atsushi Otsuka; Hideaki Miyake
Journal:  Int Cancer Conf J       Date:  2019-09-28

4.  Response to nivolumab in metastatic collecting duct carcinoma expressing PD-L1: A case report.

Authors:  Kosuke Mizutani; Kengo Horie; Shingo Nagai; Tomohiro Tsuchiya; Chiemi Saigo; Kazuhiro Kobayashi; Tatsuhiko Miyazaki; Takashi Deguchi
Journal:  Mol Clin Oncol       Date:  2017-10-12

5.  Nivolumab therapy for metastatic collecting duct carcinoma after nephrectomy: A case report.

Authors:  Shotaro Yasuoka; Tsutomu Hamasaki; Eigo Kuribayashi; Masato Nagasawa; Takanori Kawaguchi; Yoji Nagashima; Yukihiro Kondo
Journal:  Medicine (Baltimore)       Date:  2018-11       Impact factor: 1.889

6.  Metastatic Renal Medullary and Collecting Duct Carcinoma in the Era of Antiangiogenic and Immune Checkpoint Inhibitors: A Multicentric Retrospective Study.

Authors:  Zoé Guillaume; Emeline Colomba; Jonathan Thouvenin; Carolina Saldana; Luca Campedel; Clément Dumont; Brigitte Laguerre; Denis Maillet; Cécile Vicier; Frédéric Rolland; Delphine Borchiellini; Philippe Barthelemy; Laurence Albiges; Edouard Auclin; Matthieu Roulleaux Dugage; Stéphane Oudard; Constance Thibault
Journal:  Cancers (Basel)       Date:  2022-03-25       Impact factor: 6.639

Review 7.  Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease.

Authors:  Cristina Suarez; David Marmolejo; Augusto Valdivia; Rafael Morales-Barrera; Macarena Gonzalez; Joaquin Mateo; Maria Eugenia Semidey; David Lorente; Enrique Trilla; Joan Carles
Journal:  Front Oncol       Date:  2022-10-04       Impact factor: 5.738

8.  Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma.

Authors:  Tetsuya Danno; Shohei Iwata; Fusako Niimi; Sachi Honda; Haruka Okada; Takeshi Azuma
Journal:  Case Rep Urol       Date:  2021-07-02
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.